Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
791.24
-16.34 (-2.02%)
At close: Jun 17, 2025, 4:00 PM
791.89
+0.65 (0.08%)
Pre-market: Jun 18, 2025, 8:04 AM EDT
Eli Lilly Revenue
Eli Lilly had revenue of $12.73B in the quarter ending March 31, 2025, with 45.17% growth. This brings the company's revenue in the last twelve months to $49.00B, up 36.38% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$49.00B
Revenue Growth
+36.38%
P/S Ratio
14.53
Revenue / Employee
$1,042,621
Employees
47,000
Market Cap
710.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Novo Nordisk | 43.92B |
Abbott Laboratories | 42.34B |
LLY News
- 20 hours ago - Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound - Fast Company
- 23 hours ago - Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade) - Seeking Alpha
- 1 day ago - This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly - Market Watch
- 1 day ago - Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - WSJ
- 1 day ago - Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - Reuters
- 1 day ago - Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PRNewsWire
- 1 day ago - Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. - Barrons
- 1 day ago - Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - Reuters